Structural basis of inhibitor selectivity in MAP kinases.Wang, Z., Canagarajah, B.J., Boehm, J.C., Kassisa, S., Cobb, M.H., Young, P.R., Abdel-Meguid, S., Adams, J.L., Goldsmith, E.J.
(1998) Structure 6: 1117-1128
- PubMed: 9753691
- DOI: https://doi.org/10.1016/s0969-2126(98)00113-0
- Primary Citation of Related Structures:
1A9U, 1BL6, 1BL7, 1BMK, 3ERK, 4ERK
- PubMed Abstract:
The mitogen-activated protein (MAP) kinases are important signaling molecules that participate in diverse cellular events and are potential targets for intervention in inflammation, cancer, and other diseases. The MAP kinase p38 is responsive to environmental stresses and is involved in the production of cytokines during inflammation. In contrast, the activation of the MAP kinase ERK2 (extracellular-signal-regulated kinase 2) leads to cellular differentiation or proliferation. The anti-inflammatory agent pyridinylimidazole and its analogs (SB [SmithKline Beecham] compounds) are highly potent and selective inhibitors of p38, but not of the closely-related ERK2, or other serine/threonine kinases. Although these compounds are known to bind to the ATP-binding site, the origin of the inhibitory specificity toward p38 is not clear.
Department of Biochemistry The University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Boulevard, Dallas, TX 75235, USA.